![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The partnership aims at addressing the pressing global issue of hypogonadism through the launch of a comprehensive Early Access Program for Kyzatrex (testosterone undecanoate), a proprietary softgel oral formulation absorbed primarily via the lymphatic system.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Kyzatrex
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Marius Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 10, 2023